secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001599298-22-000120
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Q3 net loss $21.4M; raised $99.9M net via rights offering
-----------------------------------------------------------------------------

- Net loss $21.4M for Q3 2022 vs $19.6M prior year; 9-month net loss $59.6M vs $61.5M.
- Cash and receivables $138.4M at Sep 30, 2022, up from $89.0M at Dec 31, 2021; cash $122.0M.
- Fully subscribed Rights Offering raised $100M gross at $0.97/share, net $99.9M after $0.1M costs.
- Proceeds repaid $25M note plus accrued interest to Chairman/CEO Robert Duggan.
- Elevated Dr. Mazy Zanganeh to Co-CEO & President; discontinued pediatric ridinilazole trial; seeking partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000120/0001599298-22-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000120/smmt-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001599298-22-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer